A recent study from Chen et al. indicated that the circulating exosomal PD-L1 may reflect the states of anti-tumor immunity in melanoma patients as responders to anti-PD-1 were characterized by the increase in circulating exosomal PD-L1 during early stages of treatment [73]. Here, PDCD1 is linked to neoplasm.